Yamshchikov, Galina V.

Contribution of CpG motifs to the immunogenicity of DNA vaccines

Klinman, D. M., Yamshchikov, G., & Ishigatsubo, Y. (1997) · The Journal of Immunology

Immunotherapy and Immune ResponsesImmune Response and Inflammation

Cited by 507

A proof of concept for structure-based vaccine design targeting RSV in humans

Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science

Respiratory viral infections researchSARS-CoV-2 and COVID-19 Research

Cited by 333

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Casazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine

Virus-based gene therapy researchHIV Research and Treatment

Cited by 91

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Hamer, M. J., Houser, K. V., Hofstetter, A. R., Ortega-Villa, A. M., Lee, C., Preston, A., Augustine, B., Andrews, C., Yamshchikov, G. V., Hickman, S., et al. (2023) · The Lancet

Viral Infections and Outbreaks ResearchViral Infections and Vectors

Cited by 69